WEST LAFAYETTE, Ind. — Purdue University researchers are developing and validating a patent-pending treatment for incurable glioblastoma brain tumors. Glioblastomas are almost always lethal with a median survival time of 14 months. Traditional methods used against other cancers, like chemotherapy and immunotherapy, are often ineffective on glioblastoma. Sandro Matosevic, associate...
Latest News
Reston, VA—A new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of The Journal of Nuclear Medicine. Combining the highly specific huAR9.6 antibody with PET and therapeutic radionuclides, this theranostic platform may provide more personalized treatment to improve...
Rehovot, Israel – Researchers from Israel identified novel small molecules that can selectively lower the levels of mutant Huntington (Htt) mRNA and protein in Huntington disease (HD). These molecules reduced mitochondrial dysfunction, restored the expression of brain-derived neurotrophic factor (BDNF), improved motor function, and reduced anxious-like behavior in a mouse model...
Boston, Mass. — In the development of Parkinson’s disease (PD), the changes that will lead to neurodegeneration take place in the brain long before patients show any symptoms. But without a test that can detect these changes, it’s difficult to intervene early to more effectively slow disease progression. To address...
CLEVELAND, Ohio — NovelMed today announced that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to NM5072, an Alternative Pathway (AP) blocker anti-Properdin antibody, for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). NM5072 is being developed for PNH patients in the United States...
CLEVELAND, OHIO— NovelMed Therapeutics, Inc. today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ruxoprubart, an alternative pathway (AP) blocker anti-Bb antibody, for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). FDA’s recognition of Ruxoprubart as an orphan drug for PNH underscores its potential...
NoviSystems, a Research Triangle-area company that empowers data-driven decision making, has commercially launched Fusion Analytics, its platform to help hospitals, drug manufacturers and other complex businesses gain answers and insights that can save them time and money. NoviSystems has assembled a team of senior advisers to help apply Fusion Analytics...
Bagsværd, Denmark – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an update of the Alhemo® (concizumab) label to include the treatment of severe hemophilia A and moderate or severe haemophilia B without inhibitors. “If...
BAGSVÆRD, Denmark and PLAINSBORO, N.J. — Today, Novo Nordisk announced Mim8 (denecimig) has been submitted for review to the U.S. Food and Drug Administration (FDA) through a Biologics License Application (BLA), a formal request to evaluate a biologic medicine. Denecimig is an investigational, next-generation bispecific antibody Factor VIIIa (FVIIIa) mimetic,...
LEXINGTON, Mass. – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value...